https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-endometrial-cancer-indication-dostarlimab-gxly-chemotherapy
FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy | FDA
On August 1, 2024, the Food and Drug Administration approved dostarlimab-gxly (Jemperli, GSK) with carboplatin and paclitaxel, followed by single-agent...
endometrial cancerfdaexpandsindicationdostarlimab
https://www.jemperlihcp.com/
Primary Advanced or Recurrent Endometrial Cancer Treatment | JEMPERLI (dostarlimab-gxly)
endometrial cancer treatmentprimaryadvancedrecurrentdostarlimab